Limited coverage drugs – secukinumab

Last updated on October 7, 2022

Special Authority requests can now be submitted online. It's simple and quick!

Generic name	secukinumab
Strength	150 mg/mL
Form	Solution for subcutaneous injection

Special Authority criteria	Approval period
For the treatment of moderate to severe plaque psoriasis, according to established criteria described in Special Authority request form 5380. Coverage of secukinumab for the treatment of plaque psoriasis is only available when prescribed by a dermatologist.	First approval: 12 weeks Renewal: 1 year
For the treatment of ankylosing spondylitis, according to established criteria described in Special Authority request forms 5365 (initial/switch) and 5366 (renewal). Coverage of secukinumab for the treatment of ankylosing spondylitis is only available when prescribed by a rheumatologist.	First approval: 1 year Renewal: 1 year
For the treatment of psoriatic arthritis, according to established criteria described in Special Authority request forms 5360 (initial/switch) and 5361 (renewal). Coverage of secukinumab for the treatment of psoriatic arthritis is only available when prescribed by a rheumatologist.	First approval: 1 year Renewal: 1 year

Special Authority criteria

Approval period

For the treatment of moderate to severe plaque psoriasis, according to established criteria described in Special Authority request form 5380.

Coverage of secukinumab for the treatment of plaque psoriasis is only available when prescribed by a dermatologist.

First approval: 12 weeks
Renewal: 1 year

For the treatment of ankylosing spondylitis, according to established criteria described in Special Authority request forms 5365 (initial/switch) and 5366 (renewal).

Coverage of secukinumab for the treatment of ankylosing spondylitis is only available when prescribed by a rheumatologist.

First approval: 1 year
Renewal: 1 year

For the treatment of psoriatic arthritis, according to established criteria described in Special Authority request forms 5360 (initial/switch) and 5361 (renewal).

Coverage of secukinumab for the treatment of psoriatic arthritis is only available when prescribed by a rheumatologist.

First approval: 1 year
Renewal: 1 year

Practitioner exemptions

None

Special notes

PharmaCare covers a maximum of 30 days per fill for secukinumab.

Special Authority requests

See practitioner/prescriber requirements above

Did you find what you were looking for?

The B.C. Public Service acknowledges the territories of First Nations around B.C. and is grateful to carry out our work on these lands. We acknowledge the rights, interests, priorities, and concerns of all Indigenous Peoples - First Nations, Métis, and Inuit - respecting and acknowledging their distinct cultures, histories, rights, laws, and governments.

More topics

Limited coverage drugs – secukinumab

Practitioner exemptions

Special notes

Special Authority requests